Current Report Filing (8-k)
08 September 2015 - 2:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 8, 2015
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada |
|
000-54986 |
|
46-0524102 |
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
of incorporation) |
|
File Number) |
|
Identification No.) |
235 Walnut Street, Suite 6 |
|
Framingham, Massachusetts |
01702 |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (617) 431-2313
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On September 8, 2015, Arch Therapeutics, Inc. (the “Company”)
issued a press release announcing that the Company obtained additional safety data for its AC5 Surgical Hemostatic DeviceTM
in a standardized systemic preclinical toxicity test in animals. The text of the press release is attached hereto as Exhibit 99.1
and is incorporated by reference herein.
Item 9.01 | Financial Statements and Exhibit |
(d) Exhibits
Exhibit |
|
Description |
99.1 |
|
Press Release issued by Arch Therapeutics, Inc. on September 8, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARCH THERAPEUTICS, INC. |
|
|
Dated: September 8, 2015 |
By: |
/s/ Terrence W. Norchi, M.D. |
|
Name: |
Terrence W. Norchi, M.D. |
|
Title: |
President, Chief Executive Officer |
Exhibit
List
Exhibit |
|
Description |
99.1 |
|
Press Release issued by Arch Therapeutics, Inc. on September 8, 2015 |
Exhibit 99.1
Arch Therapeutics Obtains Additional
Positive Safety Data for AC5
Surgical Hemostatic DeviceTM in Preclinical Toxicity Test of
Sensitization
Test Result Further Supports the AC5™
Biocompatibility Profile
FRAMINGHAM, MA – September 8, 2015 — Arch
Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic
Device™ (“AC5™”), obtained favorable data from a preclinical toxicology test for AC5™ showing that
the device did not cause sensitizing reactions in animals and is considered a “non-sensitizer.” The test, called the
Maximization Test, is a standardized test of contact sensitization and is performed in animals as a major component of the biocompatibility
test panel that a medical device must typically complete successfully prior to use in humans. Testing was conducted under the guidelines
provided by the International Organization for Standardization (ISO) and the study also complied with Good Laboratory Practice
(GLP), a Federal regulation (21 CFR part 58) governing the conduct of nonclinical laboratory studies that support or are intended
to support applications for research or marketing permits for products regulated by the Food and Drug Administration (FDA). AC5
is a development-stage hemostasis product being evaluated to control bleeding, mitigate fluid loss, and create an environment permissive
to normal healing in order to provide more efficient surgical and interventional care.
In this standard in vivo study, designed to provide general
information on the health hazards likely to arise from acute exposure to clinically relevant quantities of AC5, AC5 was well tolerated
when using standardized success criteria based upon comparison with control materials. As a result, AC5 was classified as a non-sensitizer
with no evidence of causing delayed contact sensitization. Results from this biocompatibility safety study indicate that AC5’s
peptide structure and mechanism of action, which is based on the formation of a local physical-mechanical barrier at the wound
site, does not promote sensitization to the overall biological system following application of standardized AC5 extract solutions
in animals. The results of this study provide further evidence of the absence of toxicity for AC5, and represent a critical step
toward demonstrating biocompatibility of this medical device.
Arch Therapeutics President and CEO Terrence Norchi, MD, stated,
“We remain pleased with the safety data generated for AC5, and we hope and anticipate that the safety profile of our products
will represent an important distinguishing feature. This sensitization test adds to the portfolio of solid results. Tests such
as this are important for us to be able to initiate our first clinical trial, which we intend to commence after we receive the
go-ahead from the relevant bodies.”
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking
(sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology
platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate,
known as the AC5 Surgical Hemostatic Device, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.
Find out more at www.archtherapeutics.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements"
as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange
Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include
any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include,
among other things, references to novel technologies and methods, our business and product development plans and projections, or
market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors.
Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating
as a development stage company, our ability to retain important members of our management team and attract other qualified personnel,
our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements
are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any
beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any
such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set
forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the
SEC, available at www.sec.gov.
On Behalf of the Board,
Terrence W. Norchi, MD
Arch Therapeutics, Inc.
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
Or
Richard Davis
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617-431-2308
Email: rdavis@archtherapeutics.com
Website: www.archtherapeutics.com
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024